As of 2024-12-15, the Intrinsic Value of Oramed Pharmaceuticals Inc (ORMP) is
0.55 USD. This ORMP valuation is based on the model Peter Lynch Fair Value.
With the current market price of 2.47 USD, the upside of Oramed Pharmaceuticals Inc is
-77.58%.
ORMP Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(118.38) - (9.33) |
(17.48) |
-807.6% |
| DCF (Growth 10y) |
(9.63) - (109.97) |
(17.18) |
-795.4% |
| DCF (EBITDA 5y) |
(3.45) - (4.74) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(4.81) - (6.51) |
(1,234.50) |
-123450.0% |
| Fair Value |
0.55 - 0.55 |
0.55 |
-77.58% |
| P/E |
2.18 - 2.77 |
2.51 |
1.4% |
| EV/EBITDA |
(3.06) - (2.14) |
(2.91) |
-217.7% |
| EPV |
(4.47) - (6.78) |
(5.63) |
-327.9% |
| DDM - Stable |
1.30 - 20.67 |
10.99 |
344.9% |
| DDM - Multi |
1.25 - 15.72 |
2.33 |
-5.6% |
ORMP Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
99.57 |
| Beta |
1.02 |
| Outstanding shares (mil) |
40.31 |
| Enterprise Value (mil) |
57.46 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.22% |
| Cost of Debt |
7.00% |
| WACC |
6.50% |